Mitral Regurgitation Clinical Trial
— CINCH-2Official title:
A Study of Percutaneous Repair of Functional Mitral Regurgitation Using the Ancora Heart, Inc. AccuCinch® Ventricular Repair System - The CINCH-2 Study
NCT number | NCT00800046 |
Other study ID # | 1436 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | November 2008 |
Est. completion date | January 2021 |
Verified date | July 2021 |
Source | Ancora Heart, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Prospective single-arm study of the AccuCinch® Ventriculoplasty System in the treatment of mitral valve regurgitation through subvalvular mitral repair. Purpose: To demonstrate the safety, feasibility and potential efficacy of using the AccuCinch® Ventriculoplasty System to reduce mitral valve regurgitation through subvalvular mitral repair.
Status | Completed |
Enrollment | 16 |
Est. completion date | January 2021 |
Est. primary completion date | November 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 years - Severity of FMR: = Moderate (i.e., 2+) - Ejection Fraction: = 20% to =60% - Symptom Status: NYHA II-IVa - Treatment and compliance with optimal guideline directed medical therapy for heart failure for at least 1 month - Surgical risk: Subject is eligible for cardiac surgery (specific EuroSCORE (LES or ESII), STS, or comorbidities should demonstrate high risk features) - Completion of all qualifying diagnostic and functional tests and agrees to comply with study follow-up schedule Exclusion Criteria: - Significant organic mitral valve pathology (e.g. myxomatous degeneration, mitral valve prolapse or flail leaflets) - Myocardial infarction or any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 30 days - Prior surgical, transcatheter, or percutaneous mitral valve intervention - Untreated clinically significant coronary artery disease (CAD) requiring revasularization - Hemodynamic instability: Hypotension (systolic pressure <90 mmHg) or requirement for inotropic support or mechanical hemodynamic support - Any planned cardiac surgery within the next 6 months (including right heart procedures) - NYHA class (i.e., non-ambulatory) or ACC/AHA Stage D heart failure - Fixed pulmonary artery systolic pressure >70 mmHg - Severe tricuspid regurgitation (per ASE guidelines and graded by the Echo Core Lab) - Modified Rankin Scale = 4 disability - Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other structural heart disease causing heart failure other than dilated cardiomyopathy of either ischemic or non-ischemic etiology - Mitral valve area less than 4.0 cm2 - Anatomical pathology/contraints preventing appropriate access/ implant of the AccuCinch System - Renal insufficiency (i.e., eGFR of <30ml/min/1.73m2 ; Stage 4 or 5 CKD) - Moderate or severe aortic valve stenosis or regurgitation or aortic valve prosthesis Fluoroscopic or echocardiographic evidence of severe aortic arch calcification, mobile aortic atheroma, intracardiac mass, thrombus or vegetation - Active bacterial endocarditis - History of stroke within the prior 3 months - Subjects in whom anticoagulation or antiplatelet therapy is contraindicated - Known allergy to nitinol, polyester, or polyethylene - Any prior true anaphylactic reaction to contrast agents; defined as known anaphylactoid or other non-anaphylactic allergic reactions to contrast agents that cannot be adequately pre-medicated prior to the index procedure. - Life expectancy < 1 year due to non-cardiac conditions - Currently participating in another interventional investigational study - Implant or revision of any rhythm management device (CRT or CRTD) or implantable cardioverter defibrillator within 1 month - Absence of CRT with class I indication criteria for biventricular pacing (left bundle branch block pattern and QRS duration =150 ms) - On high dose steroids or immunosuppressant therapy - Female subjects who are pregnant or lactating |
Country | Name | City | State |
---|---|---|---|
Austria | Medical University of Vienna | Vienna | |
Germany | University Hospital Freiburg-Bad Krozingen | Bad Krozingen | |
Germany | Immanuel Klinikum Bernau Herzzentrum Brandenburg | Bernau | |
Germany | St.-Johannes-Hospital | Dortmund | |
Germany | Universitätsklinikum Düsseldorf | Düsseldorf | |
Germany | Cardiovascular Center Frankfurt | Frankfurt | |
Germany | Medical Care Center Hamburg University Cardiovascular Center | Hamburg | |
Lithuania | Vilnius University Hospital Santaros Klinikos | Vilnius |
Lead Sponsor | Collaborator |
---|---|
Ancora Heart, Inc. |
Austria, Germany, Lithuania,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety through 30 days and reduction in MR acutely and at 30 days. | 30 days | ||
Secondary | Safety and reduction in MR at 1 year. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03278574 -
Flexible Band vs Rigid Ring for Degenerative Mitral Valve Disease
|
N/A | |
Suspended |
NCT04960280 -
A Study to Evaluate a Computerized Stethoscope Called ©Voqx to Diagnose Heart Disease
|
N/A | |
Recruiting |
NCT05021614 -
Valveclip® Transcatheter Mitral Valve Repair Study
|
N/A | |
Not yet recruiting |
NCT06465745 -
AltaValve Pivotal Trial
|
N/A | |
Not yet recruiting |
NCT06167213 -
ALLIANCE Mitral: Safety and Effectiveness of SAPIEN X4 Transcatheter Heart Valve - Mitral
|
N/A | |
Withdrawn |
NCT05040451 -
Carillon Mitral Contour System for Treatment of Exercise Induced Functional Mitral Regurgitation
|
||
Withdrawn |
NCT03714412 -
Feasibility Study of Patients With Severe MR Treated With the Cardiovalve TMVR System
|
N/A | |
Recruiting |
NCT02592889 -
(MitraClip in Non-Responders to Cardiac Resynchronization Therapy)
|
Phase 4 | |
Completed |
NCT02355418 -
The Role of Myocardial Fibrosis in Degenerative Mitral Regurgitation
|
||
Completed |
NCT01841554 -
Cardioband With Transfemoral Delivery System
|
N/A | |
Not yet recruiting |
NCT01431222 -
Abrogation of Mitral Regurgitation Using the MitraClip System in High-Risk Patients Unsuitable for Surgery
|
Phase 4 | |
Not yet recruiting |
NCT03870516 -
Left Chamber Function in Mitral Regurgitation and Predicting Outcome After Replacement and Targeting for Early Surgery
|
N/A | |
Active, not recruiting |
NCT03230747 -
SAPIEN M3 EFS: Early Feasibility Study of the Edwards SAPIEN M3 System for the Treatment of Mitral Regurgitation
|
N/A | |
Enrolling by invitation |
NCT04031274 -
Transcatheter Treatment for Combined Aortic and Mitral Valve Disease. The Aortic+Mitral TRAnsCatheter (AMTRAC) Valve Registry
|
||
Completed |
NCT05836532 -
Long Term Results of Surgical and Percutaneous Double Orefices Mitral Repair in Patient With p2 Prolapse Causing Degenerative Mitral Regurgitation
|
||
Completed |
NCT05836480 -
Immediate Suboptimal Result of Mitral Valve Repair: Late Implications in a Matched Cohort Study
|
||
Completed |
NCT05850026 -
Mitral Regurgitation in Hypertrophic Obstructive Cardiomyopathy: Fix it in a Simple, Effective and Durable Way!
|
||
Recruiting |
NCT03975998 -
Dutch-AMR: Early Mitral Valve Repair Versus Watchful Waiting in Asymptomatic Patients With Severe Mitral Regurgitation
|
||
Completed |
NCT01162083 -
Identifying an Ideal Cardiopulmonary Exercise Test Parameter
|
N/A | |
Suspended |
NCT00787293 -
Study of Safety and Efficacy of the Percutaneous Reduction of Mitral Valve Regurgitation in Heart Failure Patients
|
Phase 2 |